BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35628700)

  • 1. Probiotic Yeast
    Abid R; Waseem H; Ali J; Ghazanfar S; Muhammad Ali G; Elasbali AM; Alharethi SH
    J Fungi (Basel); 2022 Apr; 8(5):. PubMed ID: 35628700
    [No Abstract]   [Full Text] [Related]  

  • 2. Health-promoting properties of
    Ansari F; Alian Samakkhah S; Bahadori A; Jafari SM; Ziaee M; Khodayari MT; Pourjafar H
    Crit Rev Food Sci Nutr; 2023; 63(4):457-485. PubMed ID: 34254862
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of microencapsulation on
    Ghorbani-Choboghlo H; Nikaein D; Khosravi AR; Rahmani R; Farahnejad Z
    Iran J Microbiol; 2019 Apr; 11(2):160-165. PubMed ID: 31341571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antioxidant properties and global metabolite screening of the probiotic yeast Saccharomyces cerevisiae var. boulardii.
    Datta S; Timson DJ; Annapure US
    J Sci Food Agric; 2017 Jul; 97(9):3039-3049. PubMed ID: 27868205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptome-wide differences between Saccharomyces cerevisiae and Saccharomyces cerevisiae var. boulardii: Clues on host survival and probiotic activity based on promoter sequence variability.
    Pais P; Oliveira J; Almeida V; Yilmaz M; Monteiro PT; Teixeira MC
    Genomics; 2021 Mar; 113(2):530-539. PubMed ID: 33482324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient.
    Landaburu MF; López Daneri GA; Relloso S; Zarlenga LJ; Vinante MA; Mujica MT
    Rev Argent Microbiol; 2020; 52(1):27-30. PubMed ID: 31262611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique genetic basis of the distinct antibiotic potency of high acetic acid production in the probiotic yeast
    Offei B; Vandecruys P; De Graeve S; Foulquié-Moreno MR; Thevelein JM
    Genome Res; 2019 Sep; 29(9):1478-1494. PubMed ID: 31467028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of neoagarooligosaccharides by probiotic yeast Saccharomyces cerevisiae var. boulardii engineered as a microbial cell factory.
    Jin Y; Yu S; Liu JJ; Yun EJ; Lee JW; Jin YS; Kim KH
    Microb Cell Fact; 2021 Aug; 20(1):160. PubMed ID: 34407819
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Pais P; Almeida V; Yılmaz M; Teixeira MC
    J Fungi (Basel); 2020 Jun; 6(2):. PubMed ID: 32512834
    [No Abstract]   [Full Text] [Related]  

  • 10. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
    Everard A; Matamoros S; Geurts L; Delzenne NM; Cani PD
    mBio; 2014 Jun; 5(3):e01011-14. PubMed ID: 24917595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiome Engineering Using Probiotic Yeast:
    Kim J; Atkinson C; Miller MJ; Kim KH; Jin YS
    Microbiol Spectr; 2023 Aug; 11(4):e0078023. PubMed ID: 37436157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique Probiotic Properties and Bioactive Metabolites of Saccharomyces boulardii.
    Fu J; Liu J; Wen X; Zhang G; Cai J; Qiao Z; An Z; Zheng J; Li L
    Probiotics Antimicrob Proteins; 2023 Aug; 15(4):967-982. PubMed ID: 35608794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders.
    Kelesidis T; Pothoulakis C
    Therap Adv Gastroenterol; 2012 Mar; 5(2):111-25. PubMed ID: 22423260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the Probiotic Yeast Saccharomyces boulardii in the Healthy Mucosal Immune System.
    Hudson LE; McDermott CD; Stewart TP; Hudson WH; Rios D; Fasken MB; Corbett AH; Lamb TJ
    PLoS One; 2016; 11(4):e0153351. PubMed ID: 27064405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-Galactomannan and Saccharomyces cerevisiae var. boulardii modulate the immune response against Salmonella enterica serovar Typhimurium in porcine intestinal epithelial and dendritic cells.
    Badia R; Brufau MT; Guerrero-Zamora AM; Lizardo R; Dobrescu I; Martin-Venegas R; Ferrer R; Salmon H; Martínez P; Brufau J
    Clin Vaccine Immunol; 2012 Mar; 19(3):368-76. PubMed ID: 22301691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strain engineering and metabolic flux analysis of a probiotic yeast Saccharomyces boulardii for metabolizing L-fucose, a mammalian mucin component.
    Kim J; Cheong YE; Yu S; Jin YS; Kim KH
    Microb Cell Fact; 2022 Oct; 21(1):204. PubMed ID: 36207743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yeasts as probiotics: Mechanisms, outcomes, and future potential.
    Sen S; Mansell TJ
    Fungal Genet Biol; 2020 Apr; 137():103333. PubMed ID: 31923554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probiotic Saccharomyces cerevisiae strains as biotherapeutic tools: is there room for improvement?
    Palma ML; Zamith-Miranda D; Martins FS; Bozza FA; Nimrichter L; Montero-Lomeli M; Marques ET; Douradinha B
    Appl Microbiol Biotechnol; 2015 Aug; 99(16):6563-70. PubMed ID: 26142388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Saccharomyces cerevisiae var. boulardii in food processing: a review.
    Lazo-Vélez MA; Serna-Saldívar SO; Rosales-Medina MF; Tinoco-Alvear M; Briones-García M
    J Appl Microbiol; 2018 Oct; 125(4):943-951. PubMed ID: 29961970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Mutation in
    Liu JJ; Zhang GC; Kong II; Yun EJ; Zheng JQ; Kweon DH; Jin YS
    Appl Environ Microbiol; 2018 May; 84(10):. PubMed ID: 29523547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.